ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Advisors Approve Program To Link Radiation Oncologists.

June 29, 2001

Proof of principle needed before launching “big science” program, advisors say.

March 11, 2005

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992

NTP Board Approves Concept For New Mutagenesis Assays

January 1, 1988

In Brief: Brian Henderson Names New Director Of USC Comprehensible Cancer Center, Norris Hospital

April 8, 1983

NCI brings in grantees to explain their work, promise of nanotech, to advisory board.

July 16, 2004